Bavarian Nordic hires new chairman of the board
Van Odijk has served as a board member for the company since 2008. After retiring as president and CEO of Teva Pharmaceuticals Europe B.V. in 2012, van Odijk used his long-time experience from various executive positions to serve as an independent advisor for the pharmaceutical industry. He previously held multiple senior positions at GlaxoSmithKline.
"After having served on the board for more than five years, we are happy to welcome Gerard as new chairman of the board," Anders Hedegaard, the president and CEO of Bavarian Nordic, said. "His inside knowledge from our company combined with his extensive executive background within publicly traded companies in the international pharmaceutical industry will contribute to our continued progress in the coming years."
Van Odijk is also chairman of the board of Merus Biopharmaceuticals B.V. and a member of the board of UDG Healthcare plc. He succeeds Asger Aamund, who was chairman of Bavarian Nordic's board since 1994.
The board also elected Anders Pedersen to the position of deputy chairman of the board. Pedersen is the executive vice president of research and development at H. Lundbeck A/S.